Early warning diagnosis marker for retained fetal membranes of dairy cow and application of early warning diagnosis marker
By detecting the expression level of bta-miR-1 in cow serum, providing early warning markers to predict the risk of insemination, solving the problem of difficulty in early warning and preventing insemination in the prior art, reducing the incidence rate and improving cow production Performance effect.
Patent Information
- Application Number
- CN202411366457.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-29
- Publication Date
- 2024-11-15
AI Technical Summary
The lack of seborrheic clothing is a disease that seriously endangers the reproductive health of dairy cows, leading to a decrease in milk production and reproductive performance of dairy cows, and may cause other diseases, such as mastitis, laminitis and endometriitis, and its incidence is relatively high. It is difficult to effectively warn and prevent technology.
Using bta-miR-1 in serum as an early warning and diagnostic marker, by detecting the expression level of bta-miR-1 in serum 3-5 days before delivery, a kit is provided to predict the risk of insemination of dairy cows and take precautions and treatments in advance. measure.
Through bta-miR-1 detection, it can effectively warn that the seborrheic clothing will not be lowered, reduce the incidence rate after delivery, improve the production performance of dairy cows, and increase the economic income of the dairy cattle breeding industry.
Smart Images

Figure CN118957102A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of biomedicine, and in particular to an early warning diagnostic marker for retained placenta in dairy cows and an application thereof. Background Art
[0002] Retained foetal membranes (RFM), also known as retained foetal membranes, is a disease that seriously endangers the reproductive health of dairy cows. Its main feature is that the foetus cannot be completely expelled from the body within 12 hours after the fetus is delivered. The main pathological feature is that part or all of the foetus is retained in the uterus of the dairy cow, and the foetus retained in the uterus is corrupted and causes inflammation. And retained foetus can occur in various livestock, but because dairy cows and their fetuses have a unique placental connection structure and the unique production performance of dairy cows, the incidence of retained foetus is much higher than that of other livestock. And its occurrence is common in various cattle farms. In addition, retained foetus not only has a high incidence rate, but also can cause a variety of other diseases. For example, cows with retained foetus can increase their probability of mastitis by 6-8 times, increase the incidence of laminitis by 5-7 times, and most cows with retained foetus will cause dominant or recessive endometritis to varying degrees. Therefore, when a cow suffers from retained placenta, its milk production rate and reproductive performance can be seriously affected. In addition, if the sick cow is not properly managed and treated, the undischarged placenta will rot and deteriorate in the cow's uterus, which may cause sepsis and death of the cow.
[0003] It can be seen that retained placenta has brought huge economic losses to the dairy industry. Therefore, it is of great significance to improve the production performance of dairy cows to find effective early warning markers in the early stage of peripartum and take preventive measures in time to reduce the incidence of retained placenta after parturition. Summary of the invention
[0004] The purpose of the present invention is to provide an early warning diagnostic marker for retained placenta in dairy cows and its application to solve the problems existing in the above-mentioned prior art. The early warning diagnostic marker can effectively warn of retained placenta in dairy cows, which is conducive to timely taking preventive measures, thereby reducing the incidence of retained placenta after delivery, which is of great significance for improving the production performance of dairy cows and increasing the economic income of dairy cow farming.
[0005] To achieve the above object, the present invention provides the following solutions:
[0006] The invention provides an early warning diagnostic marker for retained afterbirth in dairy cows, wherein the early warning diagnostic marker is bta-miR-1 in serum.
[0007] Furthermore, the early warning diagnostic marker is bta-miR-1 in the serum 3-5 days before delivery.
[0008] Furthermore, the expression level of the early warning diagnostic marker is upregulated, indicating that the risk of retained placenta in dairy cows is increased.
[0009] The present invention also provides the use of a reagent for detecting the expression level of the early warning diagnostic marker in the preparation of a product for predicting retained afterbirth in dairy cows.
[0010] Furthermore, the product is a kit.
[0011] Furthermore, the reagent is a primer pair.
[0012] The present invention also provides a product for predicting retained afterbirth in dairy cows, comprising a reagent for detecting the expression level of the above-mentioned early warning diagnostic marker.
[0013] Furthermore, the product is a kit.
[0014] Furthermore, the reagent is a primer pair.
[0015] The present invention discloses the following technical effects:
[0016] The present invention found that serum bta-miR-1 can be used as an early warning diagnostic marker for early detection and early warning of retained placenta in dairy cows, with an AUC value of 0.941, a sensitivity of 90.5%, and a specificity of 89.3%, showing that its predictive value is high. The early warning diagnostic marker provided by the present invention can effectively warn of retained placenta in dairy cows, which is conducive to taking preventive and control measures in time, thereby reducing the incidence of retained placenta after delivery, which is of great significance for improving the production performance of dairy cows and increasing the economic income of dairy farming. BRIEF DESCRIPTION OF THE DRAWINGS
[0017] In order to more clearly illustrate the embodiments of the present invention or the technical solutions in the prior art, the drawings required for use in the embodiments will be briefly introduced below. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without paying creative work.
[0018] Figure 1 The expression levels of bta-miR-1 in serum and maternal tissues at different time points; "*" indicates P < 0.05 compared with the control group, "**" indicates P < 0.01 compared with the control group;
[0019] Figure 2 is the mRNA expression level of serum bta-miR-1 5 days before delivery; "*" indicates P < 0.05 compared with the control group, "**" indicates P < 0.01 compared with the control group;
[0020] Figure 3 is the mRNA expression level of serum bta-miR-1 3 days before delivery; "*" indicates P < 0.05 compared with the control group, "**" indicates P < 0.01 compared with the control group;
[0021] Figure 4 It is the statistical graph of the expression rate of bta-miR-1 in serum 5 days and 3 days before delivery;
[0022] Figure 5 This is the receiver operating characteristic curve of serum bta-miR-1 3 days before delivery. DETAILED DESCRIPTION
[0023] Various exemplary embodiments of the present invention will now be described in detail. This detailed description should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features, and embodiments of the present invention.
[0024] It should be understood that the terms described in the present invention are only for describing a particular embodiment and are not intended to limit the present invention. In addition, for the numerical range in the present invention, it should be understood that each intermediate value between the upper and lower limits of the scope is also specifically disclosed. The intermediate value in any stated value or stated range, and each smaller range between any other stated value or intermediate value in the described range is also included in the present invention. The upper and lower limits of these smaller ranges can be independently included or excluded in the scope.
[0025] Unless otherwise indicated, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art. Although the present invention describes only preferred methods and materials, any methods and materials similar or equivalent to those described herein may also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe the methods and / or materials associated with the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail.
[0026] It will be apparent to those skilled in the art that various modifications and variations may be made to the specific embodiments of the present invention description without departing from the scope or spirit of the present invention. Other embodiments derived from the present invention description will be apparent to those skilled in the art. The present invention description and examples are exemplary only.
[0027] The words “include,” “including,” “have,” “contain,” etc. used in this document are open-ended terms, meaning including but not limited to.
[0028] Example 1
[0029] 1 Experimental Materials and Methods
[0030] 1.1 Reagents and instruments
[0031] 1.1.1 Experimental reagents
[0032] The main experimental reagents and production companies required in this example are shown in Table 1.
[0033] Table 1 Experimental reagents and production companies
[0034]
[0035] 1.1.2 Experimental instruments
[0036] The main instruments and production companies required for this example are shown in Table 2.
[0037] Table 2 Experimental instruments and production companies
[0038]
[0039]
[0040] 1.2 Experimental methods
[0041] 1.2.1 Sample collection
[0042] A large-scale dairy farm in Jixi City, Heilongjiang Province, selected cows with similar age, parity, weight, milk production and body condition scores, and screened and confirmed to have no other potential diseases as the research subjects of this experiment. The cows were divided into two groups according to whether the afterbirth could be naturally discharged from the body 12 hours after delivery: if the afterbirth was not completely discharged from the body within 12 hours, it was judged as RFM cows (n = 32); if the afterbirth was successfully discharged from the body within 12 hours, it was judged as healthy cows, and healthy cows (n = 32) were used as the control group (Control).
[0043] 1.2.1.1 Tissue sample collection
[0044] When the cows naturally expelled the afterbirth within 12 hours after delivery, the maternal placental tissue was immediately collected as the negative control group; if the afterbirth was not completely expelled 12 hours after delivery, the maternal placental tissue was collected in time as the RFM positive control group. After the samples were collected, they were rinsed with physiological saline to remove blood stains, and then they were packaged and quickly stored in liquid nitrogen. After being transported back to the laboratory, they were stored at -80℃ and taken out when needed.
[0045] 1.2.1.2 Serum sample collection
[0046] Serum was collected from RFM cows 7d, 5d, 3d, 1d before delivery and 0h and 12h after delivery. 10mL of blood was drawn from the tail vein of the cow. The blood sample was immediately injected into a blood collection tube without any substance added, and then left to stand at room temperature for 1h and centrifuged at 4000rpm for 5min. After centrifugation, the supernatant was transferred to an RNA-free EP tube and quickly stored in liquid nitrogen. After being transported back to the laboratory, it was stored at -80℃ and taken out when needed.
[0047] 1.2.2RT-qPCR (tailing method)
[0048] 1.2.2.1 Primer design and synthesis
[0049] The primers in this example were designed and synthesized by Sangon Biotech (Shanghai) Co., Ltd. according to the tailing method. The expression level of bta-miR-1 was detected by RT-qPCR, U6 was used as an internal reference, and the primer sequences are shown in Table 3.
[0050] Table 3 Primer sequences
[0051]
[0052] 1.2.2.2 Tissue miRNA extraction
[0053] According to the instructions of SanPrep Column microRNA Extraction Kit, miRNA was extracted from tissues. The specific steps are as follows: 50 mg of tissue sample was placed in an RNA-free EP tube, 1 mL of miRNAExtractor lysis buffer was added, the tissue was fully ground in liquid nitrogen, and the lysed sample was allowed to stand at room temperature for 10 min to completely separate the nucleoprotein from the nucleic acid. Subsequently, 200 μL of chloroform was added, vortexed for 30 s, and allowed to stand at room temperature for 3 min. After standing, centrifuged at 12000 rpm and 4 °C for 10 min. After centrifugation, the upper aqueous phase was taken to a new RNA-free EP tube, 1 / 3 volume of anhydrous ethanol was added, and the mixture was gently shaken. The Spin Column TR adsorption column was placed in a collection tube, and all the mixed liquid was added to the Spin Column TR, allowed to stand at room temperature for 1 min, centrifuged at 12000 rpm for 2 min, and the flow-through was collected in a new RNA-free EP tube. Anhydrous ethanol 2 / 3 volume of the flow-through was added to the EP tube of the flow-through, and the mixture was gently shaken. Add all the mixed liquid to the Spin Column MR adsorption column, let it stand at room temperature for 1 minute, and centrifuge at 12000rpm for 2 minutes. After centrifugation, discard the liquid in the collection tube, add 500μL RPE Solution, let it stand at room temperature for 2 minutes, centrifuge at 10000rpm for 30s, discard the liquid in the collection tube, and repeat this step twice. Place the Spin Column MR adsorption column in the clean bench and let it stand for 20 minutes to fully dry, place the adsorption column in a new RNA-free EP tube, add 20μL DEPC water to the center of the adsorption membrane, let it stand at room temperature for 2 minutes, centrifuge at 12000rpm for 2 minutes, and store the obtained miRNA in a -80℃ refrigerator until it is taken out for use.
[0054] 1.2.2.3 Extraction of serum miRNA
[0055] According to the instructions of miRcute Serum / Plasma miRNA Isolation Kit, miRNA was extracted from serum. The specific steps are as follows: 200 μL serum was taken into a new RNA-free EP tube, 900 μL MZA lysis solution was added, and vortexed for 30 seconds until completely homogenized. The sample was allowed to stand at room temperature for 5 minutes to completely separate the nucleic acid-protein complex in the sample. 200 μL chloroform was added to the sample, vortexed for 15 seconds, and allowed to stand at room temperature for 5 minutes. After standing, centrifuged at 12000 rpm and 4°C for 15 minutes. After centrifugation, the supernatant of the sample was transferred to a new RNA-free EP tube, and 2 times the volume of anhydrous ethanol of the transfer solution was slowly added and mixed. The obtained mixed liquid and precipitate were transferred to the adsorption column miRelute, allowed to stand at room temperature for 2 minutes, and centrifuged at 12000 rpm for 30 seconds. After centrifugation, the effluent was discarded, and 700 μL of protein removal solution MRD was added to the adsorption column miRelute, allowed to stand at room temperature for 2 minutes, centrifuged at 12000 rpm for 30 seconds, and the waste liquid was discarded. Add 500 μL of rinse solution RW to the adsorption column miRelute, let it stand at room temperature for 2 minutes, centrifuge at 12000rpm for 30 seconds, discard the waste liquid, and repeat this step twice. Discard the waste liquid of the adsorption column miRelute, centrifuge at room temperature for 2 minutes at 12000rpm, and discard the collection tube containing the waste liquid again. Finally, remove the miRelute and put it in the clean bench to dry, and remove the residual rinse solution in miRulte to avoid affecting the subsequent experimental results. After drying, put the adsorption column miRelute into a new EP tube, add 20 μL of DEPC water to the center of the adsorption membrane, let it stand at room temperature for 2 minutes, centrifuge at 12000rpm for 2 minutes, and store the obtained miRNA in a -80℃ refrigerator for use.
[0056] 1.2.2.4 Reverse transcription
[0057] Follow Mir-X TM miRNA First Strand Synthesis Instructions: Reverse transcribe serum and tissue sample miRNA into cDNA. The reverse transcription system is shown in Table 4. Place the configured system in a PCR amplification instrument. The reaction program is 37°C for 1h, 85°C for 5min, and after cooling to room temperature, add 90μL of DEPC water and mix well. Store in a -20°C refrigerator and take out when needed.
[0058] Table 4 Reverse transcription system
[0059]
[0060] 1.2.2.5 Real-time fluorescence quantitative PCR
[0061] According to TB Premix Ex Taq TMThe PCR amplification reaction was carried out according to the instruction manual to detect the expression level of bta-miR-1. The reaction system is shown in Table 5. The reaction procedure is: 95℃10s, 95℃5s, 60℃20s, a total of 40 cycles; 95℃60s, 55℃30s, 95℃30s. -△△ct Method to analyze the experimental results.
[0062] Table 5 miRNA PCR reaction system
[0063]
[0064] 2 Results
[0065] 2.1 Screening of bta-miR-1 expression levels in serum and maternal tissues
[0066] The changing trends of bta-miR-1 expression levels in serum and maternal tissues at 12 h postpartum of RFM cows at different time points (7d, 5d, 3d, 1d before delivery and 0h, 12h after delivery) were screened. Figure 1 As shown in the data, bta-miR-1 expression was extremely significantly upregulated in the serum at 7 days and 5 days before delivery, and in the maternal tissue at 12 hours after delivery (P<0.01); and was significantly upregulated in the serum at 3 days and 1 day before delivery, and in the serum at 0 hours and 12 hours after delivery (P<0.05), and showed a trend of increasing in the same direction.
[0067] 2.2 Verification of bta-miR-1 expression levels in serum at 5 and 3 days before delivery
[0068] Verify the changing trend of bta-miR-1 expression level in serum of 32 RFM cows 5 days and 3 days before delivery, such as Figure 2-Figure 3 As shown, 25 samples in the serum 5 days before delivery were extremely significantly upregulated (P<0.01), 4 samples were significantly upregulated (P<0.05), and 3 samples were significantly downregulated (P<0.05); 18 samples in the serum 3 days before delivery were extremely significantly upregulated (P<0.01), 12 samples were significantly upregulated (P<0.05), and 2 samples were significantly downregulated (P<0.05). Figure 4 As shown in Table 6, in the analysis of 14 serum samples, the prediction accuracy of bta-miR-1 up-regulation 5 days before delivery in dairy cows was 90.63%, and the down-regulation rate was 9.38%; the prediction accuracy of up-regulation 3 days before delivery was increased to 93.75%, and the down-regulation rate was 6.25%, and this day was used as the earliest warning detection time of bta-miR-1.
[0069] Table 6bta-miR-1 validation results information
[0070]
[0071] 2.3 Predictive Value
[0072] The receiver operating characteristic curve of serum bta-miR-1 3 days before delivery was drawn, and the results are shown in Figure 5 and Table 7. The results showed that the AUC value of using the concentration of bta-miR-1 in serum to warn of retained placenta in dairy cows reached 0.941, with a sensitivity of 90.5% and a specificity of 89.3%, indicating that its predictive value was high.
[0073] Table 7 Receiver operating characteristic curve analysis results
[0074] Markers AUC Optimal threshold Sensitivity Specificity bta-miR-1 0.941 0.798 0.905 0.893
[0075] The embodiments described above are only descriptions of the preferred modes of the present invention, and are not intended to limit the scope of the present invention. Without departing from the design spirit of the present invention, various modifications and improvements made to the technical solutions of the present invention by ordinary technicians in this field should all fall within the protection scope determined by the claims of the present invention.
Claims
1. A diagnostic marker for retained afterbirth in dairy cows, characterized in that: The early warning diagnostic marker is bta-miR-1 in serum.
2. The early warning diagnostic marker according to claim 1, characterized in that: The early warning diagnostic marker is bta-miR-1 in the serum 3-5 days before delivery.
3. The early warning diagnostic marker according to claim 1 or 2, characterized in that: The increased expression level of the early warning diagnostic marker indicates that the risk of retained placenta in dairy cows is increased.
4. Use of a reagent for detecting the expression level of the early warning diagnostic marker according to any one of claims 1 to 3 in the preparation of a product for predicting retained afterbirth in dairy cows.
5. The use according to claim 4, characterized in that: The product is a test kit.
6. The use according to claim 4, characterized in that: The reagents are primer pairs.
7. A product for predicting retained afterbirth in dairy cows, characterized in that: Comprising a reagent for detecting the expression level of the early warning diagnostic marker described in any one of claims 1-3.
8. The product according to claim 7, characterized in that The product is a test kit.
9. The product according to claim 7, characterized in that The reagents are primer pairs.
